NO20054630L - Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser - Google Patents
Anvendelser av IL-23-agonister og -antagonister, beslektede reagenserInfo
- Publication number
- NO20054630L NO20054630L NO20054630A NO20054630A NO20054630L NO 20054630 L NO20054630 L NO 20054630L NO 20054630 A NO20054630 A NO 20054630A NO 20054630 A NO20054630 A NO 20054630A NO 20054630 L NO20054630 L NO 20054630L
- Authority
- NO
- Norway
- Prior art keywords
- agonists
- antagonists
- applications
- related reagents
- methods
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45367203P | 2003-03-10 | 2003-03-10 | |
PCT/US2004/007198 WO2004081190A2 (en) | 2003-03-10 | 2004-03-09 | Uses of il-23 agonists and antagonists; related reagents |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054630L true NO20054630L (no) | 2005-10-07 |
NO20054630D0 NO20054630D0 (no) | 2005-10-07 |
Family
ID=32990805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054630A NO20054630D0 (no) | 2003-03-10 | 2005-10-07 | Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser |
Country Status (23)
Country | Link |
---|---|
US (4) | US7282204B2 (es) |
EP (2) | EP1601694B1 (es) |
JP (4) | JP4605798B2 (es) |
CN (1) | CN1759123B (es) |
AT (1) | ATE440864T1 (es) |
AU (2) | AU2004219625B9 (es) |
BR (1) | BRPI0408247A (es) |
CA (1) | CA2518262C (es) |
CL (1) | CL2004000467A1 (es) |
CY (1) | CY1109468T1 (es) |
DE (1) | DE602004022781D1 (es) |
DK (1) | DK1601694T3 (es) |
ES (1) | ES2330220T3 (es) |
HK (1) | HK1076477A1 (es) |
MX (1) | MXPA05009717A (es) |
NO (1) | NO20054630D0 (es) |
NZ (2) | NZ541898A (es) |
PL (1) | PL1601694T3 (es) |
PT (1) | PT1601694E (es) |
SI (1) | SI1601694T1 (es) |
TW (2) | TWI439285B (es) |
WO (1) | WO2004081190A2 (es) |
ZA (1) | ZA200506879B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
DE60328823D1 (de) | 2002-10-30 | 2009-09-24 | Genentech Inc | Hemmung von il-17 produktion |
BRPI0408247A (pt) * | 2003-03-10 | 2006-03-01 | Schering Corp | usos de antagonistas e agonistas de il-23 e reagentes relacionados |
EP1623011B1 (en) * | 2003-05-09 | 2013-01-02 | Janssen Biotech, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
AU2005215527B2 (en) * | 2004-02-17 | 2011-04-07 | Merck Sharp & Dohme Corp. | Methods of modulating IL-23 activity; related reagents |
US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
WO2005086835A2 (en) * | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics |
AR051444A1 (es) * | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
WO2006068987A2 (en) * | 2004-12-20 | 2006-06-29 | Schering Corporation | Uses of il-23 antagonists in the treatment of diabetes mellitus |
PT2452694T (pt) * | 2005-06-30 | 2019-02-21 | Janssen Biotech Inc | Anticorpos anti-il-23, composições, métodos e utilizações |
AU2012258409B2 (en) * | 2005-06-30 | 2016-01-07 | Centocor, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
CA2612785A1 (en) * | 2005-06-30 | 2007-01-11 | Archemix Corp. | Polynucleotides and polypeptides of the il-12 family of cytokines |
CA2619052A1 (en) * | 2005-08-25 | 2007-03-01 | Eli Lily And Company | Anti-il-23 antibiodies |
EP2354160A1 (en) * | 2005-08-31 | 2011-08-10 | Schering Corporation | Engineered anti-IL-23-antibodies |
EP2116258A1 (en) | 2005-09-01 | 2009-11-11 | Schering Corporation | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease |
KR101210395B1 (ko) * | 2005-12-29 | 2012-12-11 | 얀센 바이오테크 인코포레이티드 | 인간 항-il-23 항체, 조성물, 방법 및 용도 |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
EP1882699A1 (en) * | 2006-07-27 | 2008-01-30 | Heinfried Radeke | Regulation of interleukin-23 |
TWI426918B (zh) * | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
MX2009009080A (es) | 2007-02-23 | 2009-11-02 | Schering Corp | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. |
TR201821029T4 (tr) | 2007-02-23 | 2019-01-21 | Merck Sharp & Dohme | Geliştirilmiş antı-IL-23p19 antikorları. |
CN101668531B (zh) * | 2007-02-28 | 2014-05-07 | 默沙东公司 | 用于治疗免疫病症的联合治疗 |
EP2395025A1 (en) | 2007-02-28 | 2011-12-14 | Schering Corporation | Engineered Anti-IL-23R Antibodies |
US20100190710A1 (en) * | 2007-07-06 | 2010-07-29 | Valorisation Hsj, Societe En Commandite | Il-23 receptor antagonists and uses thereof |
AR068723A1 (es) * | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
WO2009054454A1 (ja) | 2007-10-24 | 2009-04-30 | National University Corporation Tokyo Medical And Dental University | カテプシン阻害剤を有効成分として含有するToll様受容体のシグナル伝達の調整剤 |
CA2721713C (en) | 2008-05-05 | 2019-07-09 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
US20110158992A1 (en) * | 2008-08-27 | 2011-06-30 | Schering Corporation | Engineered Anti-IL-23R Antibodies |
US20110183859A1 (en) * | 2008-09-25 | 2011-07-28 | The United States Of America, As Represented By The Secretary, | Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis |
WO2010046530A1 (en) * | 2008-10-20 | 2010-04-29 | Helsingin Yliopiston Rahastot | Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes |
US20120128689A1 (en) * | 2009-04-01 | 2012-05-24 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
MX2011011729A (es) * | 2009-05-05 | 2012-04-10 | Novimmune Sa | Anticuerpo anti il-17f y metodos de uso de los mismos. |
US20120269765A1 (en) * | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
US20110086806A1 (en) * | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Polypeptides that Bind IL-23R |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
EP3456740A1 (en) | 2010-11-04 | 2019-03-20 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
USRE49026E1 (en) | 2011-06-14 | 2022-04-12 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
EA201401204A1 (ru) | 2012-05-03 | 2015-05-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Антитела к il-23p19 |
ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
AR094877A1 (es) | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
KR102523914B1 (ko) | 2014-09-03 | 2023-04-19 | 베링거잉겔하임인터내쇼날유한회사 | Il-23a 및 tnf-알파를 표적으로 하는 화합물 및 이의 용도 |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
US11279754B2 (en) | 2015-03-11 | 2022-03-22 | Rush University Medical Center | Compositions and methods for treating cancer |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3618871A4 (en) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
MA55149A (fr) | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6176962B1 (en) | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
US5552284A (en) | 1991-03-29 | 1996-09-03 | Genentech, Inc. | Detection of interleukin-8 receptors by nudeic acid hybridization |
US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
WO1997003715A1 (en) | 1995-07-21 | 1997-02-06 | The General Hospital Corporation | Method and apparatus of enhancing the delivery of a pharmaceutical formulation |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
US5842787A (en) | 1997-10-09 | 1998-12-01 | Caliper Technologies Corporation | Microfluidic systems incorporating varied channel dimensions |
US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
DE69942671D1 (de) | 1998-12-01 | 2010-09-23 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
HU230679B1 (en) * | 1999-09-09 | 2017-08-28 | Merck Sharp & Dohme | Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
NZ522146A (en) * | 2000-05-10 | 2004-10-29 | Schering Corp | Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5 |
AU2318202A (en) * | 2000-10-06 | 2002-04-15 | Immunex Corp | Hematopoietin receptors hpr1 and hpr2 |
WO2002097048A2 (en) * | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
BRPI0408247A (pt) * | 2003-03-10 | 2006-03-01 | Schering Corp | usos de antagonistas e agonistas de il-23 e reagentes relacionados |
-
2004
- 2004-03-09 BR BRPI0408247-8A patent/BRPI0408247A/pt not_active IP Right Cessation
- 2004-03-09 AU AU2004219625A patent/AU2004219625B9/en not_active Ceased
- 2004-03-09 JP JP2006507006A patent/JP4605798B2/ja not_active Expired - Fee Related
- 2004-03-09 AT AT04718824T patent/ATE440864T1/de active
- 2004-03-09 SI SI200431281T patent/SI1601694T1/sl unknown
- 2004-03-09 PL PL04718824T patent/PL1601694T3/pl unknown
- 2004-03-09 WO PCT/US2004/007198 patent/WO2004081190A2/en active Application Filing
- 2004-03-09 ES ES04718824T patent/ES2330220T3/es not_active Expired - Lifetime
- 2004-03-09 DE DE602004022781T patent/DE602004022781D1/de not_active Expired - Lifetime
- 2004-03-09 US US10/797,157 patent/US7282204B2/en active Active
- 2004-03-09 TW TW100126443A patent/TWI439285B/zh not_active IP Right Cessation
- 2004-03-09 DK DK04718824T patent/DK1601694T3/da active
- 2004-03-09 PT PT04718824T patent/PT1601694E/pt unknown
- 2004-03-09 CL CL200400467A patent/CL2004000467A1/es unknown
- 2004-03-09 CN CN2004800067148A patent/CN1759123B/zh not_active Expired - Fee Related
- 2004-03-09 EP EP04718824A patent/EP1601694B1/en not_active Expired - Lifetime
- 2004-03-09 NZ NZ541898A patent/NZ541898A/en not_active IP Right Cessation
- 2004-03-09 TW TW093106213A patent/TWI357336B/zh not_active IP Right Cessation
- 2004-03-09 MX MXPA05009717A patent/MXPA05009717A/es active IP Right Grant
- 2004-03-09 CA CA2518262A patent/CA2518262C/en not_active Expired - Fee Related
- 2004-03-09 EP EP09163834.6A patent/EP2108658B1/en not_active Expired - Lifetime
- 2004-03-09 NZ NZ567860A patent/NZ567860A/en not_active IP Right Cessation
-
2005
- 2005-08-26 ZA ZA200506879A patent/ZA200506879B/en unknown
- 2005-10-07 NO NO20054630A patent/NO20054630D0/no not_active Application Discontinuation
- 2005-12-07 HK HK05111191.9A patent/HK1076477A1/xx not_active IP Right Cessation
-
2007
- 2007-02-26 JP JP2007046287A patent/JP2007197453A/ja active Pending
- 2007-08-31 US US11/848,462 patent/US20080057058A1/en not_active Abandoned
-
2009
- 2009-08-24 US US12/546,230 patent/US8034341B2/en not_active Expired - Lifetime
- 2009-10-06 CY CY20091101030T patent/CY1109468T1/el unknown
-
2010
- 2010-08-16 AU AU2010212372A patent/AU2010212372B2/en not_active Ceased
- 2010-09-07 JP JP2010200382A patent/JP2011032275A/ja not_active Withdrawn
-
2011
- 2011-10-10 US US13/270,077 patent/US20120034219A1/en not_active Abandoned
-
2013
- 2013-08-15 JP JP2013168870A patent/JP2014005286A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054630L (no) | Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser | |
NO20064194L (no) | Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser | |
NO20053590D0 (no) | Dobbel modusenhet for kortdistanse, hoyrate og langstanse, lavere dataratekommunikasjon. | |
ATE515514T1 (de) | Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien | |
EP2283860A3 (en) | Use for interleukin-33 (il-33) and the il-33 receptor complex | |
TW200531679A (en) | Methods of modulating cytokine activity; related reagents | |
NO20052496D0 (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
NO20073293L (no) | Toll-liknende reseptor-3-antagonister, fremgangsmater og anvendelser | |
DK1287140T3 (da) | Antistofmolekyler, der har specificitet overfor human tumornekrosefaktor-alfa og anvendelse deraf | |
DE60331355D1 (de) | Steuerung für multimedia-sitzungen | |
DE60327103D1 (de) | Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer | |
IS7815A (is) | 3-Fenýl setið pýridóindólón, framleiðsla og meðferðarleg notkun þess. | |
WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
SE0301650D0 (sv) | Novel compounds | |
DE602004008589D1 (de) | Informationskommunikationssystem, sendevorrichtung, sendeverfahren und computerprogramm | |
DE60326773D1 (de) | Peptid-deformylase-hemmer | |
MXPA05012297A (es) | Indazol que tiene actividad analgesica. | |
DE60207833D1 (de) | Peptiddeformylase-hemmer | |
ITMI20021917A1 (it) | Attivatore per la formazione di gel piastrinico, gel di plasma povero di piastrine o gel di plasma ricco di piastrine. | |
BR0308321A (pt) | Inibidores da peptìdeo deformilase | |
ITRM20020358A1 (it) | Composizione estetico-farmaceutica per applicazione topica, procedimento per la sua produzione e suoi impieghi. | |
ITPV20020004A1 (it) | Dispositivo per miscelare o amalgamare vernici, pitture o simili. | |
AU2003301174A8 (en) | Liposomal analgesic formulation and use | |
UA2986U (uk) | Спосіб лікування розсіяного склерозу | |
AU2013204147A1 (en) | Treatment of TNFalpha related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP, US Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |